Ikena Oncology Ikena Oncology
  • Contact
  • Linked
  • Twitter
  • About
    • Our Company
    • Leadership
    • Partners
    • Contact
  • Focus
    • Our Approach
    • Publications
  • Pipeline
    • Development Pipeline
    • IK-930 TEAD Inhibitor
    • RAS Signaling
    • IK-175 AHR Antagonist
    • IK-412 Kynase Program
    • IK-007 EP4 Antagonist
  • Careers
    • Culture
    • Job Opportunities
  • Investors & Media
    • Corporate Profile
    • Press Releases
    • Events & Presentations
    • Stock Information
      • Stock Quote & Chart
    • Financial Filings
      • SEC Filings
    • Corporate Governance
      • Documents & Charters
      • Management Team
      • Board of Directors
    • Investor Resources
      • Investor FAQs
      • Investor Email Alerts
      • Contact IR
Select Page
    • About
      • Our Company
      • Leadership
      • Partners
      • Contact
    • Focus
      • Our Approach
      • Publications
    • Pipeline
      • Development Pipeline
      • IK-930 TEAD Inhibitor
      • RAS Signaling
      • IK-175 AHR Antagonist
      • IK-412 Kynase Program
      • IK-007 EP4 Antagonist
    • Careers
      • Culture
      • Job Opportunities
    • Investors & Media
      • Corporate Profile
      • Press Releases
      • Events & Presentations
      • Stock Information
        • Stock Quote & Chart
      • Financial Filings
        • SEC Filings
      • Corporate Governance
        • Documents & Charters
        • Management Team
        • Board of Directors
      • Investor Resources
        • Investor FAQs
        • Investor Email Alerts
        • Contact IR
    • Contact
    • Privacy Policy
    • Terms of Use
    • Linked
    • Twitter

Contact IR

Site - Side

  • Corporate Profile
  • Press Releases
  • Events & Presentations
  • Stock Information
    • Stock Quote & Chart
    • Historic Price Lookup
    • Analyst Coverage
  • Financial Filings
    • SEC Filings
  • Corporate Governance
    • Documents & Charters
    • Management Team
    • Board of Directors
  • Investor Resources
    • Investor FAQs
    • Investor Email Alerts
    • Contact IR

Investors & Media Contact

  • Rebecca Cohen
  • rcohen@ikenaoncology.com

Tools

  • Print Page
  • Email Alerts
  • RSS Feeds
Footer Logo
Ikena Oncology
645 Summer Street
Suite 101
Boston, MA 02210
  • About
  • Our Company
  • Leadership
  • Partners
  • Contact
  • Focus
  • Ikena™ Approach
  • Publications
  • Pipeline
  • Development Pipeline
  • IK-930 TEAD Inhibitor
  • RAS Signaling
  • IK-175 AHR Antagonist
  • IK-412 Kynase Program
  • IK-007 EP4 Antagonist
  • Careers
  • Culture
  • Job Opportunities
  • Investors & Media
  • Corporate Profile
  • Press Releases
  • Events & Presentations
  • Stock Information
  • Financial Filings
  • Corporate Governance
  • Investor Resources
  • Privacy Policy
  • Terms of Use
  • Linked
  • Twitter
© 2021 Ikena Oncology™